著者

Mami Wakabayashi Yasunori Ichimura Eiichi Shimizu Tomoko Nishioka Yuzuru Kono Masahiko Doi Yuriko Egami Tomoka Kadowaki Hiroyasu Iso Noriko Fujita

出版者

National Center for Global Health and Medicine

雑誌

GHM Open (ISSN:2436293X)

巻号頁・発行日

pp.2021.01032, (Released:2022-02-26)

参考文献数

20

被引用文献数

1

---

The World Health Organization (WHO) has been utilizing Emergency Use Listing (EUL) to expand access to medical products during the COVID-19 pandemic. EUL is a risk-based procedure for assessing and listing unlicensed vaccines, medicine, and in vitro diagnostics. To determine whether Japanese medical products acquired EUL relating to COVID-19, we conducted desk research as a part of a new project. Results showed that thirteen of twenty-eight in vitro diagnostic products were from China and three of ten vaccines on EUL were from India. However, only one vaccine manufactured in Japan was on EUL. A common weakness of Japanese companies in the global public procurement market was a lack of knowledge on qualification systems for medical products. We hypothesized holistic approaches from private companies and systematic supports from public sectors are required for a response to an emergency. These activities could lead to contribute to global health issues through sustainable businesses.